AIM
TGTX icon

Axiom Investment Management’s TG Therapeutics TGTX Stock Holding History

Axiom Investment Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.41K Hold
62
– – ﹤0.01% 424
2026
Q1 		$2.06K Buy
+62
New +$1.85K ﹤0.01% 364
2022
Q4 		– Sell
-62
Closed – – 403
2022
Q3 		$0 Buy
+62
New +$407 ﹤0.01% 459

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Axiom Investment Management's TGTX Position: Q2 2026 in Review

Axiom Investment Management held its TG Therapeutics (TGTX) position steady in Q2 2026 at 62 shares worth $3.41K. The position accounts for ﹤0.01% of the portfolio, ranked #424.

Axiom Investment Management first reported a position in TGTX in Q3 2022 and has held it in 3 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Axiom Investment Management held 62 shares of TG Therapeutics worth $3.41K as of Q2 2026.
  • Axiom Investment Management left its TG Therapeutics share count unchanged in Q2 2026.
  • TG Therapeutics made up ﹤0.01% of Axiom Investment Management's portfolio in Q2 2026, its #424 holding.
  • Axiom Investment Management first reported a position in TG Therapeutics in Q3 2022 and has held it in 3 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Axiom Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.